In this episode we discuss:
Join us on the latest episode! Our Guest: J.D. Mowery, CEO of KBI Biopharma
What you’ll get out of this episode:
- Mowery’s progression from the chemical industry to biopharma leadership.
- Exploration of Mowery’s experiences in the industry
- KBI BioPharma: Insights into the company’s impact and role in the biopharmaceutical industry.
- Discussion on KBI BioPharma’s international facilities and outreach.
- Mowery shares his strategic vision for KBI BioPharma and the evolving CDMO industry.
- A focus on the importance of customer relationships and collaborative approaches in biopharma.
- Mowery’s thoughts on the future of biopharma and leadership.
Watch
Listen
Read
Introduction
In a recent episode of the BioBreakthroughs podcast, host Jared S. Taylor welcomed J.D. Mowery, CEO of KBI BioPharma, for an in-depth discussion. They explored Mowery’s extensive experience in the biopharmaceutical industry and his vision for KBI BioPharma.
J.D. Mowery’s Background and Ascent to CEO
J.D. Mowery’s journey in the biopharmaceutical industry is a tale of consistent progress and adaptation. His career began in the chemical industry, eventually leading him to the biopharma space in 2007 with a small molecule sterile injectable organization in Ohio. His pivotal role in the company’s success, including the launch of a significant generic product, marked the beginning of his ascent in the industry.
Mowery’s experience spans across various roles and companies, including Genentech, Global WemSat, Lonza, and AGC Biologics. His involvement in these companies provided him with a holistic view of the biopharmaceutical landscape, particularly in drug product facilities and CDMO operations. In 2022, he joined Treadwell Therapeutics as Chief Operating Officer before moving to KBI BioPharma as CEO.
The Role of KBI BioPharma in Biopharmaceuticals
KBI BioPharma, under Mowery’s leadership, is positioned as a next-generation Contract Development and Manufacturing Organization (CDMO). The company specializes in tackling complex molecules and processing challenges, offering a range of services from clinical to commercial manufacturing in various areas like mammalian and microbial spaces, and cell therapy. With facilities across North Carolina, Colorado, Texas, Belgium, and Switzerland, KBI’s global presence enables it to offer a seamless, integrated service to its clients.
Vision for the Future
Mowery’s vision for KBI BioPharma revolves around three key pillars: business risk management, regulatory affairs and quality leadership, and innovation through R&D. He emphasizes the importance of partnerships over transactional relationships in the CDMO space, aiming to provide solutions even before customers realize their needs.
Slice Of Healthcare Wrap
J.D. Mowery’s journey to the CEO of KBI BioPharma is a testament to the evolving nature of the biopharmaceutical industry. His forward-thinking approach and dedication to innovation position KBI BioPharma as a leader in the CDMO space.
WORD FROM OUR SPONSORS:
Our sponsor for this episode are Sage Growth Partners.
Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media – @sagegrowthpartners
Learn more about KBI Biopharma follow these links:
– Guest’s LinkedIn – LinkedIn – Website –
Also, be sure to follow Slice of Healthcare on our social channels:
– Website – LinkedIn – Twitter – YouTube – Newsletter –
